Integrative multi-ancestry genetic analysis of gene regulation in coronary arteries prioritizes disease risk loci

Abstract

Genome-wide association studies (GWAS) have identified hundreds of genetic risk loci for coronary artery disease (CAD). However, non-European populations are underrepresented in GWAS and the causal gene-regulatory mechanisms of these risk loci during atherosclerosis remain unclear. We incorporated local ancestry and haplotype information to identify quantitative trait loci (QTL) for gene expression and splicing in coronary arteries obtained from 138 ancestrally diverse Americans. Of 2,132 eQTL-associated genes (eGenes), 47% were previously unreported in coronary arteries and 19% exhibited cell-type-specific expression. Colocalization analysis with GWAS identified subgroups of eGenes unique to CAD and blood pressure. Fine-mapping highlighted additional eGenes of interest, including TBX20 and IL5. Splicing (s)QTLs for 1,690 genes were also identified, among which TOR1AIP1 and ULK3 sQTLs demonstrated the importance of evaluating splicing events to accurately identify disease-relevant gene expression. Our work provides the first human coronary artery eQTL resource from a patient sample and exemplifies the necessity of diverse study populations and multi-omic approaches to characterize gene regulation in critical disease processes.

• Download figure
• Open in new tab

Competing Interest Statement

J.L.M.B is a shareholder in Clinical Gene Network AB and has an invested interest in STARNET. J.C.K. is the recipient of an Agilent Thought Leader Award, which includes funding for research that is unrelated to the current manuscript. S.W.vdL. has received Roche funding for unrelated work. C.L.M. has received AstraZeneca funding for unrelated work. All other authors declare that they have no competing interests relevant to the contents of this paper to disclose.

Funding Statement

This work was supported by grants from: the National Institutes of Health (grant numbers R01HL148239 and R01HL164577 to C.L.M; T32HL007284 to C.J.H; and R01HL125863 to J.L.M.B; R01HL130423, R01HL135093 and R01HL148167 to J.C.K.); the American Heart Association (grant number 20POST35120545 to A.W.T.; AHA909150 to J.V.M.; A14SFRN20840000 to J.L.M.B.); the Swedish Research Council and Heart Lung Foundation (grant number 2018-02529 and 20170265 to J.L.M.B.); the Fondation Leducq (grant number 18CVD02 to C.L.M., J.L.M.B) and the Single-Cell Data Insights award from the Chan Zuckerberg Initiative, LLC and Silicon Valley Community Foundation (to C.L.M). This work was also supported by fellowship grants from the Bench to Bassinet Pediatric Cardiac Genomics Consortium (PCGC) & Cardiovascular Development Data Resource Center (CDDRC) (to C.J.H).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

Institutional Review Board (IRB) of Stanford University (protocols #4237 and #11925) and of University of Virginia (protocol #20008) gave ethical approval for the procurement and use of human tissues and information.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes